A great obstacle to HIV vaccine development is the resistance of primary isolates of HIV to neutralization. During the previous funding period for this grant, we have developed substantial data regarding mechanisms of neutralization resistance and the nature of primary virus cross-reactive neutralization.
The aims of the current proposal build on our previous findings.
Aim 1 of the proposed studies is to define structure-function relationships that determine the neutralization resistance (NR) and high infectivity (HI) phenotypes characteristics of the primary HIV-1-MN envelope, MNP. We have a family of envelopes that vary in neutralization resistance over a range of 205-fold. Among the parent clones and a large number of chimeric clones derived from them there is a very strong correlation between NR and infectivity. Our studies demonstrated that these phenotypes are determined by functional interactions of the leucine zipper (LZ) structure in gp41 with the amino and carboxyl terminal segments of gp120 and the downstream gp41 alpha helix. The mutations in gp120 that are present in the MNP clone cluster on the surface of the molecule in three regions: the CD4bs, the putative chemokine receptor binding site, and a region that we hypothesize to be the gp41 binding site. We hypothesize that a functional balance among the gp120 interactions with its three ligands and the interactions between the alpha helical regions in the gp41 ectodomain determine neutralization resistance. In this aim we will study molecular and functional mechanisms responsible for the global neutralization resistance, enhanced inefectivity phenotype.
Aim 2 of the proposed studies is to define mechanisms that determine resistance or sensitivity of primary strains of HIV-1 to neutralization to antibodies directed against the conformation sensitive neutralization epitope at the apex of the V3 loop. Our previous studies have demonstrated that some primary isolates are neutralized by antibody against such epitope appears to contribute to primary virus cross-reactive neutralization. Since this is a highly conserved structure, it is a significant target for immunization. Studies will be conducted to determine mechanisms of resistance to neutralization at this epitope.
Aim 3 of the proposed studies is to define characteristics that contribute to capacity of HIV envelopes to induce primary virus cross-reactive neutralizing antibodies. Previous studies have demonstrated that envelope with extensive neutralizing cross-reactivity from the donor of HIV- Neutralizing Serum (2) has an intermediate neutralization sensitivity phenotype and the capacity to induce primary virus cross reactive neutralization when administered in a alpha virus expression vector. Neutralization sensitivity and immunogenicity of envelopes from similar donors will be studied. These findings are highly relevant to vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI037438-09
Application #
6893408
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Ahlers, Jeffrey D
Project Start
1995-06-01
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2008-03-31
Support Year
9
Fiscal Year
2005
Total Cost
$259,350
Indirect Cost
Name
Henry M. Jackson Fdn for the Adv Mil/Med
Department
Type
DUNS #
144676566
City
Rockville
State
MD
Country
United States
Zip Code
20817
Defang, Gabriel N; Khetawat, Dimple; Broder, Christopher C et al. (2010) Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29:212-20
Quinnan Jr, Gerald V; Yu, Xiao-Fang; Lewis, Mark G et al. (2005) Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol 79:3358-69
Zhang, Peng Fei; Bouma, Peter; Park, Eun Ju et al. (2002) A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76:644-55
Park, E J; Gorny, M K; Zolla-Pazner, S et al. (2000) A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 74:4183-91
Park, E J; Quinnan Jr, G V (1999) Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol 73:5707-13
Chabot, D J; Zhang, P F; Quinnan, G V et al. (1999) Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol 73:6598-609
Quinnan Jr, G V; Zhang, P F; Fu, D W et al. (1998) Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants. AIDS Res Hum Retroviruses 14:939-49